Financial data tables

Novavax (NVAX) figures from its financial statements (company filings via Financial Modeling Prep), in US dollars; non-US reporters are converted to US dollars. Periods carry the company's own fiscal quarter and year, as its filings name them, with the date each period ended. Source filings are on the Filings tab.

Novavax quarterly results
PeriodRevenueGross profitOperating incomeNet incomeDiluted EPSGross marginOperating margin
Q3 FY2026 (ended Sep 30, 2026)$68.0M$45.0M-$31.0M-$31.0M-$0.1965.6%-45.8%
Q2 FY2026 (ended Jun 30, 2026)$57.0M$42.0M-$55.0M-$53.0M-$0.3274.9%-96.8%
Q1 FY2026 (ended Mar 31, 2026)$140.0M$109.0M-$15.0M-$9.0M-$0.0678.0%-11.1%
Q4 FY2025 (ended Dec 31, 2025)$147.0M$122.0M$21.0M$18.0M$0.1182.9%14.3%
Q3 FY2025 (ended Sep 30, 2025)$70.0M$49.0M-$178.0M-$202.0M-$1.2569.5%-252.7%
Q2 FY2025 (ended Jun 30, 2025)$239.0M$225.0M$106.0M$107.0M$0.6094.0%44.2%
Q1 FY2025 (ended Mar 31, 2025)$667.0M$653.0M$516.0M$519.0M$2.9397.9%77.3%
Q4 FY2024 (ended Dec 31, 2024)$88.0M$52.0M-$131.0M-$81.0M-$0.5158.5%-148.4%
Novavax quarterly cash flow
PeriodOperating cash flowCapital expendituresFree cash flowShare repurchasesDividends paid
Q3 FY2026 (ended Sep 30, 2026)-$94.0M$1.0M-$95.0M$0.0M$0.0M
Q2 FY2026 (ended Jun 30, 2026)-$75.0M$1.0M-$76.0M$8.0M$0.0M
Q1 FY2026 (ended Mar 31, 2026)-$32.0M$1.0M-$34.0M$8.0M$0.0M
Q4 FY2025 (ended Dec 31, 2025)-$39.0M$2.0M-$42.0M$0.0M$0.0M
Q3 FY2025 (ended Sep 30, 2025)$108.0M$2.0M$106.0M$1.0M$0.0M
Q2 FY2025 (ended Jun 30, 2025)-$127.0M$0.0M-$128.0M$5.0M$0.0M
Q1 FY2025 (ended Mar 31, 2025)-$186.0M$2.0M-$187.0M$0.0M$0.0M
Q4 FY2024 (ended Dec 31, 2024)-$173.0M$2.0M-$175.0M$0.0M$0.0M
Novavax balance sheet
PeriodTotal assetsCash and equivalentsShort-term investmentsTotal debtTotal equity
Q3 FY2026 (ended Sep 30, 2026)$888.0M$222.0M$400.0M$295.0M-$217.0M
Q2 FY2026 (ended Jun 30, 2026)$956.0M$191.0M$528.0M$296.0M-$191.0M
Q1 FY2026 (ended Mar 31, 2026)$1.04B$228.0M$562.0M$295.0M-$145.0M
Q4 FY2025 (ended Dec 31, 2025)$1.18B$241.0M$494.0M$249.0M-$128.0M
Novavax revenue by segment
SegmentQ2 FY2026 (ended Jun 30, 2026)Q1 FY2026 (ended Mar 31, 2026)Q3 FY2025 (ended Sep 30, 2025)Q2 FY2025 (ended Jun 30, 2025)
Licensing, Royalties, and Other$38.0M
Royalties and Other$1.0M
Product$42.0M$13.0M$11.0M
Supply Sales$33.0M$14.0M$13.0M
Nuvaxovid Sales$10.0M$0.0M-$2.0M
Novavax revenue by region
RegionQ2 FY2026 (ended Jun 30, 2026)Q1 FY2026 (ended Mar 31, 2026)Q4 FY2025 (ended Dec 31, 2025)Q3 FY2025 (ended Sep 30, 2025)
United States$38.0M$96.0M$111.0M$57.0M
Rest of the World$17.0M$23.0M$33.0M$13.0M
Europe$1.0M$20.0M$3.0M$1.0M
Novavax employees
YearEmployees
2025749
2024952
20231,543
20221,992
20211,541
2020791

Novavax (NVAX) reported revenue of $68.00M in Q3 2026, with Licensing, Royalties, and Other its largest revenue segment at 98%.

Ask Sterling

Register for a premium account to gain access to Sterling AI.

Get Started

Things you can ask Sterling:

Summarize Tesla's latest earnings reportWhy did NVIDIA's margins expand?Compare Apple vs Microsoft's cash flowWhat's driving EV industry growth?
Menu
Favorites